Other Pharmaceuticals - Denmark

Denmark

In Denmark, the revenue in the market Other Pharmaceuticals market is projected to reach US$1.21bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 3.69%, resulting in a market volume of US$1.45bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$260.50bn in 2024.
Denmark is renowned for its strong focus on research and development in the pharmaceutical industry, driving innovation in the market for other pharmaceuticals.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Pharmaceuticals market in Denmark has been showing an interesting trend in recent years.

Customer preferences: Denmark is a country with a high level of healthcare expenditure, which has led to a high level of trust in the healthcare system and a preference for prescription medications. However, there is also a growing interest in natural and alternative medicine, which has impacted the Other Pharmaceuticals market.

Trends in the market: The Other Pharmaceuticals market in Denmark has been growing steadily in recent years, driven by an aging population and an increasing prevalence of chronic diseases. In addition, there has been a growing interest in natural and alternative medicine, which has led to an increase in demand for products such as herbal supplements and homeopathic remedies.

Local special circumstances: Denmark has a strong regulatory system for pharmaceuticals, which has led to a high level of quality and safety in the market. However, this has also made it difficult for new companies to enter the market, which has led to a relatively small number of players in the Other Pharmaceuticals market.

Underlying macroeconomic factors: Denmark has a strong economy with a high level of healthcare expenditure, which has supported the growth of the Other Pharmaceuticals market. In addition, Denmark has a well-educated population with a high level of health literacy, which has led to a growing interest in natural and alternative medicine. However, the high regulatory barriers to entry in the market have also made it difficult for new companies to compete, which has limited the level of innovation in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.